Shoulder Innovations (SI) Revenue & Revenue Breakdown
Shoulder Innovations Revenue Highlights
Latest Revenue (Y)
$31.62M
Latest Revenue (Q)
$11.76M
Shoulder Innovations Revenue by Period
Shoulder Innovations Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $31.62M | 64.07% |
| 2023-12-31 | $19.27M | - |
Shoulder Innovations generated $31.62M in revenue during NA 2024, up 64.07% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Shoulder Innovations Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-09-30 | $11.76M | 6.75% |
| 2025-06-30 | $11.01M | 8.70% |
| 2025-03-31 | $10.13M | 16.13% |
| 2024-12-31 | $8.72M | 17.05% |
| 2024-09-30 | $7.45M | -9.76% |
| 2024-06-30 | $8.26M | 14.98% |
| 2024-03-31 | $7.18M | 5.01% |
| 2023-12-31 | $6.84M | 54.84% |
| 2023-09-30 | $4.42M | 6.46% |
| 2023-06-30 | $4.15M | 7.37% |
| 2023-03-31 | $3.87M | - |
Shoulder Innovations generated $11.76M in revenue during Q3 2025, up 6.75% compared to the previous quarter, and up 142.32% compared to the same period a year ago.
Shoulder Innovations Revenue Breakdown
Shoulder Innovations Revenue Breakdown by Product
Quarterly Revenue by Product
| Product/Service | Sep 25 | Jun 25 |
|---|---|---|
| Reportable Segment | $11.76M | $11.01M |
Latest
Shoulder Innovations's latest quarterly revenue breakdown by segment (product or service), as of Sep 25: Reportable Segment (100.00%).
Shoulder Innovations Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| INGN | Inogen | $335.70M | $92.39M |
| OM | Outset Medical | $113.69M | $29.43M |
| MDXH | MDxHealth | $70.19M | $19.83M |
| ENTA | Enanta Pharmaceuticals | $65.32M | $18.31M |
| SNWV | SANUWAVE Health | $32.63M | $11.45M |
| SI | SHOULDER INNOVATIONS | $31.62M | $11.76M |
| NNOX | Nano-X Imaging | $9.90M | $2.55M |
| AARD | Aardvark Therapeutics | - | - |
| EPRX | Eupraxia Pharmaceuticals | - | - |
| NAUT | Nautilus Bio | - | $6.52M |
| ASMB | Assembly Biosciences | - | - |